Curative Biotechnology Stock Performance
| CUBT Stock | USD 0.01 0.0004 2.74% |
Curative Biotechnology holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -3.62, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Curative Biotechnology are expected to decrease by larger amounts. On the other hand, during market turmoil, Curative Biotechnology is expected to outperform it. Use Curative Biotechnology maximum drawdown and the relationship between the expected short fall and period momentum indicator , to analyze future returns on Curative Biotechnology.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Curative Biotechnology are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental drivers, Curative Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:400 | Last Split Date 2022-12-02 |
1 | This Biotech Stock Soared 300 percent Overnight. Why It Can Go Higher. - Barrons | 01/08/2025 |
2 | Cabaletta Bio Takes Center Stage Key Autoimmune Therapy Updates Coming at Major Biotech Conference - StockTitan | 01/29/2025 |
3 | Can Tenayas Heart Disease Therapies Impress Investors at March Conferences - StockTitan | 03/03/2025 |
| Begin Period Cash Flow | 58.7 K |
Curative |
Curative Biotechnology Relative Risk vs. Return Landscape
If you would invest 0.91 in Curative Biotechnology on December 16, 2024 and sell it today you would earn a total of 0.59 from holding Curative Biotechnology or generate 64.84% return on investment over 90 days. Curative Biotechnology is currently generating 1.9687% in daily expected returns and assumes 15.5058% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Curative, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Curative Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Curative Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Curative Biotechnology, and traders can use it to determine the average amount a Curative Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CUBT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.51 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.97 actual daily | 39 61% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Curative Biotechnology is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Curative Biotechnology by adding it to a well-diversified portfolio.
Curative Biotechnology Fundamentals Growth
Curative Stock prices reflect investors' perceptions of the future prospects and financial health of Curative Biotechnology, and Curative Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Curative Stock performance.
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 14.87 M | ||||
| Shares Outstanding | 903.26 M | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (3.96 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 2.26 M | ||||
| Debt To Equity | 6.60 % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (486.58 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Market Capitalization | 13.59 M | ||||
| Total Asset | 2.6 M | ||||
| Retained Earnings | (38.23 M) | ||||
| Working Capital | (4.42 M) | ||||
About Curative Biotechnology Performance
Assessing Curative Biotechnology's fundamental ratios provides investors with valuable insights into Curative Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Curative Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 1.4 K | |
| Return On Tangible Assets | (4.43) | (4.21) | |
| Return On Capital Employed | 0.55 | 0.58 | |
| Return On Assets | (2.57) | (2.44) | |
| Return On Equity | 1.67 | 1.75 |
Things to note about Curative Biotechnology performance evaluation
Checking the ongoing alerts about Curative Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Curative Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Curative Biotechnology is way too risky over 90 days horizon | |
| Curative Biotechnology has some characteristics of a very speculative penny stock | |
| Curative Biotechnology appears to be risky and price may revert if volatility continues | |
| Curative Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Curative Biotechnology currently holds 2.26 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 132.32 K. Net Loss for the year was (3.96 M) with profit before overhead, payroll, taxes, and interest of 100.21 K. | |
| Curative Biotechnology currently holds about 126.85 K in cash with (486.58 K) of positive cash flow from operations. | |
| Curative Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Can Tenayas Heart Disease Therapies Impress Investors at March Conferences - StockTitan |
- Analyzing Curative Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Curative Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Curative Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Curative Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Curative Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Curative Biotechnology's stock. These opinions can provide insight into Curative Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.